NASDAQ: NSPRInspiremd Inc Stock
$0.71-0.03 (-4.05%)
Updated Jun 18, 2026
NSPR Price
$0.71
Fair Value Price
N/A
Market Cap
$33.26M
52 Week Low
$0.69
52 Week High
$2.93
P/E
-1x
P/B
0.76x
P/S
12.59x
PEG
N/A
Dividend Yield
N/A
Revenue
$10.85M
Earnings
-$51.31M
Gross Margin
28.1%
Operating Margin
-472.4%
Profit Margin
-473%
Debt to Equity
0.3
Operating Cash Flow
-$39M
Beta
0.53
Next Earnings
N/A
Ex-Dividend
N/A
Next Dividend
N/A
NSPR Overview
InspireMD, Inc., an Israel-based medical technology company established in 2005, specializes in creating and commercializing advanced medical devices. Its core expertise lies in the proprietary MicroNet stent platform technology, engineered to address various vascular and coronary diseases. The company's offerings, distributed through a network of local partners, reach markets across Europe, Latin America, the Middle East, and Asia Pacific. Key products include the CGuard carotid embolic prevention system, specifically designed for carotid artery procedures, and the MGuard Prime embolic protection systems. The MGuard Prime systems are crucial for patients experiencing acute coronary syndromes, notably acute myocardial infarction, and those undergoing saphenous vein graft coronary interventions or bypass surgery. InspireMD is also developing PVGuard, an innovative solution combining a MicroNet mesh sleeve with a self-expandable stent, aimed at peripheral vascular applications.
Zen Rating
Our proven quant model uses 115 proprietary factors, including AI, to determine NSPR's potential to beat the market
- NSPR doesn't meet the minimum data requirements for our proprietary Zen Ratings model. Learn more about Zen Ratings.
Zen Rating Component Grades
N/A
N/A
N/A
N/A
N/A
N/A
N/A
Zen Rating uses advanced AI algorithms that detect subtle patterns in market data; it anticipates future trends that point to superior stock price results.
Industry: Medical Device
Industry Rating
C
NSPR
RankedUnranked of 93
RankedUnranked of 93
Top Ranked Stocks in Industry
| Name / Ticker | Price | Zen Rating |
|---|---|---|
| $8.71 | A | |
| $38.68 | A | |
| $26.62 | A |
Be the first to know about important NSPR news, forecast changes, insider trades & much more!
NSPR News
Overview
Due Diligence Score
–
Industry Average (29)
You've viewed Due Diligence Score for 10/10 free stocks. Upgrade to Premium to see how NSPR scored across 33 valuation, financial, forecast, performance, and dividend due diligence checks.
Due Diligence Checks
NSPR is unprofitable, so we are unable to calculate its intrinsic value according to an updated version of Benjamin Graham's Formula from "The Intelligent Investor"
Below Benjamin Graham Formula Value Valuation
NSPR is good value based on its book value relative to its share price (0.76x), compared to the US Medical Devices industry average (2.95x)
P/B vs Industry Valuation
NSPR is unprofitable, so we... subscribe to Premium to read more.
PEG Value Valuation
There are 30 more NSPR due diligence checks available for Premium users.
Valuation
NSPR price to earnings (PE)
For valuing profitable companies with steady earnings
Company
-1x
Industry
20.08x
Market
9.47x
NSPR price to book (PB)
For valuing companies that are loss-making or have lots of physical asset
Company
0.76x
Industry
2.95x
NSPR is good value based... subscribe to Premium to read more.
P/B vs Industry Valuation
NSPR's financial health
Profit margin
Revenue
$3.4M
Net Income
-$13.7M
Profit Margin
-402.9%
NSPR's cash and short-term investments... subscribe to Premium to read more.
Interest Coverage Financials
NSPR's profit margin has increased... subscribe to Premium to read more.
Profit Margin Growth Financials
Assets to liabilities
Assets
$56.5M
Liabilities
$12.9M
Debt to equity
0.3
NSPR's short-term assets ($48.59M) exceed... subscribe to Premium to read more.
Short-term Liabilities Financials
NSPR's short-term assets ($48.59M) exceed... subscribe to Premium to read more.
Long-term Liabilities Financials
NSPR's debt has increased relative... subscribe to Premium to read more.
Shrinking Debt Financials
NSPR's debt to equity ratio... subscribe to Premium to read more.
Healthy Debt to Equity Financials
Cash flow
Operating
-$12.3M
Investing
$14.8M
Financing
$0.0
NSPR's cash and short-term investments... subscribe to Premium to read more.
Debt Coverage Financials
NSPR vs Medical Device Stocks
Inspiremd Stock FAQ
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletterWallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.